Systematic review of lung shunt fraction quantification comparing SPECT/CT and planar scintigraphy for yttrium 90 radioembolization planning
ConclusionThe current clinical assessment of LSF is substantially overestimated by 2D planar scintigraphy when compared to 3D SPECT/CT. However, unclearness of blinding between the index test and reference standard was an area of quality concern. Hence, further randomized or prospective studies are needed to strengthen the role of SPECT/CT in lung shunt fraction estimation.
We describe our experience with a patient with recurrent metastatic lung adenocarcinoma under ICI therapy that was submitted to 67Ga scanning for a fever of unknown origin and we discuss the aforementioned topics, alongside current imaging trends and future perspectives in the field.PMID:34404012 | DOI:10.1016/j.ctarc.2021.100441
Conclusion: 18F-FDG PET/MRI is a highly specific N-staging method and improves LNM detection. Because of the limited sensitivity in frequently occurring small LNMs, PET/MRI should be combined with SLN mapping. The proposed combined protocol helps to decide whether extensive surgical staging is necessary in patients with FIGO I/II cervical cancer.
Conclusion In patients with HCC undergoing Y90-RS, mean tumour dose ≥250 Gy and minimum tumour dose of ≥180 Gy to 100% of tumour volume are both significantly correlated with higher objective tumour response and prolonged survival.
Conclusion: The diabody targeting TfR could be successfully synthesized and radiolabeled with radionuclide 99mTc using HYNIC as bifunctional chelator. 99mTc-HYNIC-diabody can specifically bind to TfR-over expression cell in vitro and in vivo, indicating its potential value in the future clinical translation.
Molecular PharmaceuticsDOI: 10.1021/acs.molpharmaceut.1c00060
To quantify the relationship of the tumor-to-normal ratio (TNR) attained from the technetium-99m macroaggregated albumin (MAA) and posttreatment yttrium-90 bremsstrahlung (Y90-Brem) single-photon emission computerized tomography (SPECT)/computer tomography (CT) studies in patients with hepatocellular carcinoma (HCC) treated with glass microspheres.
Primary liver tumor with hepatocellular carcinoma accounting for 75–80% of all such tumors, is one of the global leading causes of cancer-related death, especially in cirrhotic patients. Liver tumors are highly hypervascularized via the hepatic artery, while normal liver tissues are mainly supplied by the portal vein; consequently, intra-arterially delivered treatment, which includes transarterial chemoembolization (TACE) and transarterial radioembolization (TARE), is deemed as a palliative treatment. With the development of nuclear technology and radiochemistry, TARE has become an alternative for patients with hepat...
ConclusionPractitioners are encouraged to work towards adoption of these recommendations.
Conclusion After the administration of 1.2–3.7 GBq 188Re-HDD/lipiodol based on empirical activity calculation of 0.8–1.2 mCi/mL of tumor volume, more than half of the patients in the present study had an objective response on imaging and biochemically. No significant adverse side effects were noted and most of the laboratory markers as well as symptoms returned to normal after 48–72 h post-administration. Selective administration of the radiopharmaceutical into the tumor feeding arteries gives a good anti-tumoral effect with minimal side effects and damage to surrounding normal liver tissue.
We present a case of recurrent malignant pheochromocytoma with unusual multiple peritoneal carcinomatosis on 131I-MIBG SPECT/CT after laparoscopic adrenalectomy.